Anavex

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Anavex and other ETFs, options, and stocks.

About AVXL

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. 

CEO
Terrie Kellmeyer
CEOTerrie Kellmeyer
Employees
34
Employees34
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2004
Founded2004
Employees
34
Employees34

AVXL Key Statistics

Market cap
298.40M
Market cap298.40M
Price-Earnings ratio
-6.93
Price-Earnings ratio-6.93
Dividend yield
Dividend yield
Average volume
748.04K
Average volume748.04K
High today
$3.30
High today$3.30
Low today
$3.12
Low today$3.12
Open price
$3.18
Open price$3.18
Volume
734.53K
Volume734.53K
52 Week high
$13.99
52 Week high$13.99
52 Week low
$2.61
52 Week low$2.61

Stock Snapshot

With a market cap of 298.4M, Anavex(AVXL) trades at $3.23. The stock has a price-to-earnings ratio of -6.93.

During the trading session on 2026-05-09, Anavex(AVXL) shares reached a daily high of $3.30 and a low of $3.12. At a current price of $3.23, the stock is +3.5% higher than the low and still -2.1% under the high.

Trading activity shows a volume of 734.53K, compared to an average daily volume of 748.04K.

The stock's 52-week range extends from a low of $2.61 to a high of $13.99.

The stock's 52-week range extends from a low of $2.61 to a high of $13.99.

AVXL News

TipRanks 2d
Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling

Anavex (AVXL) Life Sciences announced that its board has appointed former senior VP of clinical development and current senior advisor Terrie Kellmeyer as inter...

Nasdaq 3d
Anavex Life Sciences Names Terrie Kellmeyer As Interim CEO

(RTTNews) - Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company, Wednesday announced that it has appointed Terrie Kellmeyer as its Int...

Anavex Life Sciences Names Terrie Kellmeyer As Interim CEO
TipRanks 3d
Anavex Life Sciences Names Interim CEO Amid Leadership Shift

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

More AVXL News

TipRanks 5d
Anavex initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw initiated coverage of Anavex (AVXL) with a Buy rating and $20 price target implying 500% upside from the current share price. The company is de...

People also own

Based on the portfolios of people who own AVXL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.